Previous 10 | Next 10 |
home / stock / silo / silo articles
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares NY Mets owner Steve Cohen has bought as many as 119,092,680 ordinary...
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy...
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Billionaire hedge fund and NY Mets own...
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next MAPS Public Benefit Corporation (MAPS PBC), the nonprofi...
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035...
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassificat...
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety Psychedelics biotech Cybin (NYSE: CYBN) and UK-bas...
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials Starting this October, scientists at Imperial Colle...
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials Starting this October, scientists at Imperial Colle...
News, Short Squeeze, Breakout and More Instantly...
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today announced that it has awarded a contract to its contract research organizati...
Amplify Bio to complete GLP study of SPC-15 Novel Intranasal Therapeutic Silo study advances SPC-15 towards first-in-human trial SARASOTA, FL, June 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmen...
Silo Pharma (NASDAQ: SILO) , a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has closed on a previously announced registered direct offering. According to the announcement, ...